Welcome to our dedicated page for Nano Dimension SEC filings (Ticker: nndm), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
nano dimension (tase: nndm, nasdaq: nndm) is a leading additive manufacturing technology company. nano dimension is disrupting, shaping and defining the future of how electronics are made. with its unique 3d printing technologies, nano dimension is targeting the growing demand for electronic devices that require increasingly sophisticated features and rely on printed circuit boards (pcbs). demand for circuitry, including pcbs - which are the heart of every electronic device - covers a diverse range of industries, including consumer electronics, medical devices, defense, aerospace, automotive, iot and telecom. these sectors can all benefit greatly from nano dimension’s 3d printed electronics solutions for rapid prototyping and short-run manufacturing. our dragonfly multi-material 3d printer family uses proprietary conductive nano-silver inks along with matched dielectric inks to make in-house agile hardware development and multi-layer pcb a reality. imagine being able to innovate and exNano Dimension Ltd. has agreed to sell its additively manufactured electronics (AME) and previously discontinued Fabrica product lines to Inspira Technologies OXY B.H.N. Ltd. for total consideration of up to $12.5 million, subject to customary regulatory approvals. The structure includes a $2.0 million upfront cash payment and up to $10.5 million in deferred payments based on the product lines’ performance over the next twelve months.
The company expects the divestiture to reduce its annualized cash burn by about $10 million, strengthen liquidity and financial flexibility, and simplify operations as part of its ongoing strategic alternatives review process to maximize shareholder value. Management determined these product lines no longer fit its go-forward priorities and plans to update 2026 financial guidance on its first quarter 2026 earnings call.
Nano Dimension Ltd. outlines a major strategic shift toward core additive manufacturing and electronics solutions while reporting a 2025 net loss of $293.4 million. The company acquired Desktop Metal for about $179.3 million and Markforged for about $115 million, then deconsolidated Desktop Metal after its Chapter 11 bankruptcy.
Management and board control changed following activist-driven disputes, and Nano Dimension transitioned from a foreign private issuer to a U.S. domestic issuer as of January 1, 2026. The business now focuses on higher-margin product lines such as DragonFly AME, Essemtec SMT, GIS inkjet systems and Markforged FFF and binder jetting solutions, supported by 468 employees and a portfolio of about 383 patents.
Nano Dimension Ltd. reported strong top-line growth for 2025 but remained unprofitable. Full-year 2025 revenue reached $102.4 million, up 77.3% from $57.8 million, helped by the Markforged acquisition. Fourth-quarter revenue was $35.3 million, a 142.4% increase year-over-year.
GAAP gross margin for 2025 was 33.5%, down from 43.1%, while non-GAAP adjusted gross margin improved to 46.9%. Adjusted EBITDA loss narrowed to $53.2 million from a $63.6 million loss. Net loss from continuing operations was $100.4 million, and net loss from discontinued operations, mainly related to Desktop Metal, was $193.3 million.
The company ended 2025 with $206.4 million in cash, cash equivalents and restricted cash and total cash, deposits and marketable equity securities of $459.6 million as of December 31, 2025. Non-GAAP operating expenses fell to $27.3 million in the fourth quarter, more than 16% below the prior baseline, reflecting cost-reduction efforts.
For 2026, Nano Dimension guides for revenue of $130–$140 million, non-GAAP gross margin of 46–48%, non-GAAP operating expenses of $106–$111 million and an adjusted EBITDA loss of $40–$50 million. The board’s strategic alternatives review continues, with a series of actions to define the company’s path forward expected in the second quarter of 2026.
NNDM filed a Form 144 reporting proposed sales of securities, including 347,221 Restricted Stock Units dated 09/08/2025. The filing also lists a prior reported sale of 136,208 Ordinary shares on 02/23/2026 by David Stehlin with a reported value of 272,375.14.
Nano Dimension Ltd. notifies the SEC it cannot timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and will use the 15‑day extension under Rule 12b-25.
The company says it ceased qualifying as a foreign private issuer effective January 1, 2026, shortening its filing window to 75 days. The Company cites the April 2025 acquisitions of Desktop Metal, Inc. and Markforged Holding Corporation, integration of different financial systems, resource limitations, and the need to complete acquisition-related disclosures and internal control documentation. Management provides preliminary, unaudited results: fourth quarter 2025 revenue of $35.3 million, full-year 2025 revenue of $102.4 million, net loss from continuing operations of $101.2 million, and total cash, cash equivalents, deposits and investable securities of $457.8 million as of December 31, 2025. The Company reports a material weakness in internal control over financial reporting related to accounting for business combinations and expects to conclude it did not maintain effective disclosure controls and procedures for 2025.
Nano Dimension Ltd. reported a sale of 136,208 American Depositary Shares on 02/24/2026. The shares represent underlying restricted stock units that vested and were sold to cover tax withholdings. The transaction was processed through CIBC Oppenheimer and involved shares listed on NASDAQ.
Oramed Pharmaceuticals Inc., a Delaware corporation, filed Amendment No. 1 to its Schedule 13D regarding Nano Dimension Ltd. Ordinary Shares. Oramed reports beneficial ownership of 10,942,087 Ordinary Shares, representing 5.2% of the class, based on 210,334,767 shares outstanding as of October 14, 2025.
On February 17 and 18, 2026, Oramed purchased an additional 1,425,000 Ordinary Shares in open market transactions for an aggregate of approximately $2,800,500, using general working capital. On February 19, 2026, Oramed sent a response letter to an affiliate of Nano Dimension, reiterating dissatisfaction with the issuer’s management and stating an intent to further engage on performance, strategic direction, shareholder value and governance.
Nano Dimension Ltd. adopted a shareholder rights plan designed to protect holders of its American Depositary Shares. The company entered into a Rights Agreement with The Bank of New York Mellon, issuing one special purchase right for each ADS outstanding at the close of business on February 13, 2026.
Each Right lets its holder buy one ADS from the company at a purchase price of $0.01 per ADS if any person or group becomes an “Acquiring Person” by beneficially owning 9.99% or more of the company’s ordinary shares, subject to detailed exceptions. Rights held by an Acquiring Person or its affiliates are void.
The Board can redeem all Rights for no consideration before anyone becomes an Acquiring Person, or later exchange exercisable Rights for ADSs at a fixed ratio, subject to limits. The Rights expire on February 1, 2027. The Board states the plan is intended to give it time to evaluate any attempt to gain significant influence and to encourage negotiations it deems in the company’s best interests.
Oramed Pharmaceuticals Inc. and its CEO Nadav Kidron filed a Schedule 13D reporting beneficial ownership of 10,549,430 Nano Dimension ordinary shares, equal to 5.0% of the class based on 210,334,767 shares outstanding as of October 14, 2025.
They invested approximately $18,247,072 to build this position, with most shares held by Oramed and 135,700 shares held personally by Mr. Kidron. The filers state they have been, and expect to continue, discussing Nano Dimension’s performance, financing options, strategy, governance, and board composition with management, directors and other shareholders, and may propose changes, pursue additional share purchases or sales, hedging transactions, or potential corporate actions depending on future circumstances.